Clinical Trial

Experimental Treatment for Lymphoproliferative Diseases

Study Description

A Study of the Safety and Efficacy of EBV Specific T-cell Lines

This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Group A

Peptide-stimulated T cells 2 x 10^7/m^2

Biological - Group B

Peptide-stimulated T cells per dose-escalation protocol

Additional Information

Official Study Title

A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases

Clinical Trial ID

NCT02580539

ParticipAid ID

5eVoOa